Wellington Management Group LLP Grows Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Wellington Management Group LLP grew its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 66.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 602,936 shares of the biopharmaceutical company’s stock after purchasing an additional 241,512 shares during the quarter. Wellington Management Group LLP’s holdings in Esperion Therapeutics were worth $995,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its position in Esperion Therapeutics by 2.7% in the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after buying an additional 99,802 shares during the period. Wasatch Advisors LP boosted its holdings in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the period. MetLife Investment Management LLC grew its stake in Esperion Therapeutics by 47.1% in the third quarter. MetLife Investment Management LLC now owns 71,050 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 22,734 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Esperion Therapeutics by 152.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 74,522 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Esperion Therapeutics during the 3rd quarter valued at $94,000. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Stock Up 0.5 %

NASDAQ ESPR opened at $2.17 on Friday. Esperion Therapeutics, Inc. has a 52 week low of $1.58 and a 52 week high of $3.94. The company has a 50 day moving average price of $2.41 and a 200 day moving average price of $2.22. The firm has a market cap of $427.57 million, a PE ratio of -3.39 and a beta of 1.01.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ESPR. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Thursday, December 12th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a report on Wednesday. They set a “neutral” rating and a $4.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a report on Tuesday. They set an “overweight” rating and a $8.00 price objective on the stock. Finally, StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and a consensus target price of $7.30.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.